Remove tag italian-medicines-agency
article thumbnail

Drug-resistant epilepsy drug Ontozry backed by NICE

pharmaphorum

The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least two prior antiseizure medicines.

Drugs 87